Department of Medical Oncology, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
Br J Cancer. 2011 Oct 25;105(9):1342-5. doi: 10.1038/bjc.2011.402. Epub 2011 Oct 4.
Immunohistological assessment of Ki 67 expression is less expensive than Oncotype Dx, which is currently used to identify patients with lymph node-negative breast cancer, who will benefit from adjuvant chemotherapy.
The relationship of immunohistologically measured Ki 67 to Oncotype DX recurrence score (RS) was examined in 53 cases of T1-2 N0 M0 (oestrogen receptor-positive, HER2/neu negative) breast cancer.
There was a strong linear correlation between Ki 67 value and the Oncotype Dx RS. All patients in the low Ki 67 group (Ki 67 of ≤ 10%) had Oncotype Dx RSs of low or intermediate risk. The vast majority of patients (93.8%) in the high-Ki 67 group (Ki 67 ≥ 25%) had oncotype RSs of high or intermediate risk.
Ki 67 proliferation value is a major, but not the sole determinant of Oncotype Dx score.
Ki67 表达的免疫组织化学评估比目前用于识别淋巴结阴性乳腺癌患者的 OncotypeDx 更便宜，这些患者将从辅助化疗中受益。
在 53 例 T1-2N0M0（雌激素受体阳性，HER2/neu 阴性）乳腺癌中，检查了免疫组织化学测量的 Ki67 与 OncotypeDX 复发评分（RS）的关系。
Ki67 值与 OncotypeDxRS 之间存在很强的线性相关性。低 Ki67 组（Ki67≤10%）的所有患者的 OncotypeDxRS 均为低或中危。高 Ki67 组（Ki67≥25%）的绝大多数患者（93.8%）的 Oncotype RS 为高或中危。
Ki67 增殖值是 OncotypeDx 评分的主要但不是唯一决定因素。
